GSK (GSK) is a GB-listed Healthcare company in Drug Manufacturers - General with a market capitalization of
01.9B, trading at $50.87 on the NYSE. This SniperIQ fundamentals page covers GSK's valuation (P/E 13.2x, P/B 4.3x), profitability (net margin 17.8%), revenue (£32.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
01.9B
P/E (TTM)13.2x
Net Margin17.8%
Revenue (FY25)£32.7B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is GSK's market cap?
GSK (GSK) has a market capitalization of approximately
01.9B, trading at $50.87 on the NYSE. Market cap moves with the live share price.
What is GSK's P/E ratio?
GSK's trailing twelve-month P/E ratio is 13.2x, with a price-to-book (P/B) of 4.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GSK?
GSK runs a net profit margin of 17.8%, a gross margin of 72.7%, and an operating margin of 22.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GSK generate?
GSK reported revenue of £32.7B for fiscal year 2025, with net income of £5.7B and earnings per share (EPS) of 5.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GSK pay a dividend?
GSK offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is GSK financially healthy?
GSK carries a debt-to-equity ratio of 1.07x and a current ratio of 0.79x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GSK a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GSK (GSK) the key facts are: market cap
01.9B, P/E 13.2x, revenue £32.7B, 52-week range 36.75-61.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GSK's full fundamentals live
Get GSK's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.